CN103373994A - 治疗性化合物 - Google Patents
治疗性化合物 Download PDFInfo
- Publication number
- CN103373994A CN103373994A CN2013101360033A CN201310136003A CN103373994A CN 103373994 A CN103373994 A CN 103373994A CN 2013101360033 A CN2013101360033 A CN 2013101360033A CN 201310136003 A CN201310136003 A CN 201310136003A CN 103373994 A CN103373994 A CN 103373994A
- Authority
- CN
- China
- Prior art keywords
- compound
- solvate
- pharmaceutically useful
- useful salt
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
Description
Claims (17)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201206908A GB201206908D0 (en) | 2012-04-19 | 2012-04-19 | Therapeutic compounds |
GB1206908.4 | 2012-04-19 | ||
GB201302704A GB201302704D0 (en) | 2012-04-19 | 2013-02-15 | Therapeutic compounds |
GB1302704.0 | 2013-02-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103373994A true CN103373994A (zh) | 2013-10-30 |
CN103373994B CN103373994B (zh) | 2017-05-03 |
Family
ID=46261583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310136003.3A Active CN103373994B (zh) | 2012-04-19 | 2013-04-18 | 治疗性化合物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9062039B2 (zh) |
EP (1) | EP2844657B1 (zh) |
CN (1) | CN103373994B (zh) |
AU (1) | AU2013250912B2 (zh) |
CA (1) | CA2908638C (zh) |
GB (2) | GB201206908D0 (zh) |
WO (1) | WO2013156780A1 (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106699608A (zh) * | 2016-12-26 | 2017-05-24 | 常州大学 | 一种含有强吸电子基团的苯胍及其盐的制备方法 |
CN107118207A (zh) * | 2017-05-22 | 2017-09-01 | 苏州东南药业股份有限公司 | 一类cdk抑制剂的制备方法 |
CN108349964A (zh) * | 2015-08-04 | 2018-07-31 | 常州千红生化制药股份有限公司 | N-(吡啶-2-基)-4-(噻唑-5-基)嘧啶-2-胺类化合物作为治疗性化合物 |
CN108658966A (zh) * | 2018-06-20 | 2018-10-16 | 常州千红生化制药股份有限公司 | 选择性cdk9抑制剂的酒石酸盐及其晶型 |
WO2018192273A1 (zh) * | 2017-04-19 | 2018-10-25 | 上海炯烁医药科技有限公司 | 一种新型细胞周期蛋白依赖性激酶cdk9抑制剂 |
CN112239466A (zh) * | 2020-11-10 | 2021-01-19 | 常州千红生化制药股份有限公司 | 选择性cdk4/6抑制剂的琥珀酸盐及其晶型 |
CN114276341A (zh) * | 2021-07-05 | 2022-04-05 | 常州英诺升康生物医药科技有限公司 | 一种ls007杂质化合物a及其制备工艺和应用 |
CN114349747A (zh) * | 2021-07-05 | 2022-04-15 | 常州英诺升康生物医药科技有限公司 | 一种ls007杂质化合物a的制备工艺 |
CN115160307A (zh) * | 2022-08-02 | 2022-10-11 | 常州英诺升康生物医药科技有限公司 | 一种ls010杂质化合物b及其制备工艺和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101309586A (zh) * | 2005-09-24 | 2008-11-19 | 拜尔农作物科学股份公司 | 用作杀菌剂的噻唑类化合物 |
CN102143953A (zh) * | 2008-03-26 | 2011-08-03 | 诺丁汉大学 | 嘧啶、三嗪类化合物以及它们作为药剂的用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005048072A1 (de) | 2005-09-24 | 2007-04-05 | Bayer Cropscience Ag | Thiazole als Fungizide |
-
2012
- 2012-04-19 GB GB201206908A patent/GB201206908D0/en not_active Ceased
-
2013
- 2013-02-15 GB GB201302704A patent/GB201302704D0/en not_active Ceased
- 2013-04-18 AU AU2013250912A patent/AU2013250912B2/en active Active
- 2013-04-18 US US14/394,830 patent/US9062039B2/en active Active
- 2013-04-18 EP EP13718047.7A patent/EP2844657B1/en active Active
- 2013-04-18 CN CN201310136003.3A patent/CN103373994B/zh active Active
- 2013-04-18 WO PCT/GB2013/050982 patent/WO2013156780A1/en active Application Filing
- 2013-04-18 CA CA2908638A patent/CA2908638C/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101309586A (zh) * | 2005-09-24 | 2008-11-19 | 拜尔农作物科学股份公司 | 用作杀菌剂的噻唑类化合物 |
CN102143953A (zh) * | 2008-03-26 | 2011-08-03 | 诺丁汉大学 | 嘧啶、三嗪类化合物以及它们作为药剂的用途 |
Non-Patent Citations (1)
Title |
---|
SHENLIN HUANG: "《Bioorganic & Medicinal Chemistry Letters》", 《SYNTHESIS AND BIOLOGICAL STUDY OF 2-AMINO-4-ARYL-5-CHLOROPYRIMIDINE ANALOGUES AS INHIBITORS OF VEGFR-2 AND CYCLIN DEPENDENT KINASE 1 (CDK1)》, vol. 17, 2 February 2007 (2007-02-02), pages 2179 - 2183 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108349964B (zh) * | 2015-08-04 | 2021-06-01 | 常州千红生化制药股份有限公司 | N-(吡啶-2-基)-4-(噻唑-5-基)嘧啶-2-胺类化合物作为治疗性化合物 |
CN108349964A (zh) * | 2015-08-04 | 2018-07-31 | 常州千红生化制药股份有限公司 | N-(吡啶-2-基)-4-(噻唑-5-基)嘧啶-2-胺类化合物作为治疗性化合物 |
CN106699608A (zh) * | 2016-12-26 | 2017-05-24 | 常州大学 | 一种含有强吸电子基团的苯胍及其盐的制备方法 |
US10952999B2 (en) | 2017-04-19 | 2021-03-23 | Genfleet Therapeutics (Shanghai) Inc. | Inhibitor of cyclin-dependent kinase CDK9 |
WO2018192273A1 (zh) * | 2017-04-19 | 2018-10-25 | 上海炯烁医药科技有限公司 | 一种新型细胞周期蛋白依赖性激酶cdk9抑制剂 |
CN107118207B (zh) * | 2017-05-22 | 2020-10-02 | 苏州东南药业股份有限公司 | 一类cdk抑制剂的制备方法 |
CN107118207A (zh) * | 2017-05-22 | 2017-09-01 | 苏州东南药业股份有限公司 | 一类cdk抑制剂的制备方法 |
WO2019242471A1 (zh) | 2018-06-20 | 2019-12-26 | 常州千红生化制药股份有限公司 | 选择性cdk9抑制剂的酒石酸盐及其晶型 |
CN108658966A (zh) * | 2018-06-20 | 2018-10-16 | 常州千红生化制药股份有限公司 | 选择性cdk9抑制剂的酒石酸盐及其晶型 |
US11566024B2 (en) | 2018-06-20 | 2023-01-31 | Changzhou Qianhong Biopharma Co., Ltd. | Tartrate of selective CDK9 inhibitor and crystal form thereof |
CN112239466A (zh) * | 2020-11-10 | 2021-01-19 | 常州千红生化制药股份有限公司 | 选择性cdk4/6抑制剂的琥珀酸盐及其晶型 |
CN112239466B (zh) * | 2020-11-10 | 2021-06-08 | 常州千红生化制药股份有限公司 | 选择性cdk4/6抑制剂的琥珀酸盐及其晶型 |
CN114276341A (zh) * | 2021-07-05 | 2022-04-05 | 常州英诺升康生物医药科技有限公司 | 一种ls007杂质化合物a及其制备工艺和应用 |
CN114349747A (zh) * | 2021-07-05 | 2022-04-15 | 常州英诺升康生物医药科技有限公司 | 一种ls007杂质化合物a的制备工艺 |
CN115160307A (zh) * | 2022-08-02 | 2022-10-11 | 常州英诺升康生物医药科技有限公司 | 一种ls010杂质化合物b及其制备工艺和应用 |
Also Published As
Publication number | Publication date |
---|---|
CA2908638C (en) | 2020-04-28 |
EP2844657B1 (en) | 2017-04-12 |
AU2013250912B2 (en) | 2017-05-25 |
GB201206908D0 (en) | 2012-06-06 |
CN103373994B (zh) | 2017-05-03 |
GB201302704D0 (en) | 2013-04-03 |
CA2908638A1 (en) | 2013-10-24 |
US20150105413A1 (en) | 2015-04-16 |
US9062039B2 (en) | 2015-06-23 |
AU2013250912A1 (en) | 2014-11-27 |
EP2844657A1 (en) | 2015-03-11 |
WO2013156780A1 (en) | 2013-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103373994A (zh) | 治疗性化合物 | |
EP3057592B1 (en) | Hepatitis b viral assembly effectors | |
CN104507931B (zh) | 新化合物 | |
JP6673920B2 (ja) | Parg阻害化合物 | |
CN105324378B (zh) | 可用作fgfr激酶调节剂的喹唑啉酮衍生物 | |
TWI602814B (zh) | 透過抑制fgfr激酶之具有抗癌性的吡啶並吡嗪衍生物化合物 | |
WO2020123395A1 (en) | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors | |
CA2914178C (en) | Deoxyuridine triphosphatase inhibitors | |
EP1373253B1 (en) | Inhibitors of cyclin dependent kinases as anti-cancer agent | |
KR20140084063A (ko) | Fgfr 키나제의 억제를 통한 항암 벤조피라진 | |
JP2017537154A (ja) | キナゾリン複素環式化合物、その製造方法及び癌を治療する上皮成長因子受容体阻害剤としての応用 | |
EA021421B1 (ru) | Производные хинолинов и хиноксалинов в качестве ингибиторов протеинтирозинкиназы, способ их получения, содержащая их фармацевтическая композиция и способ лечения заболеваний с применением таких соединений | |
CA2982562C (en) | Crystalline fgfr4 inhibitor compound and uses thereof | |
CN111386266B (zh) | 具有抑制癌细胞生长作用的新型嘧啶衍生物及包含其的药物组合物 | |
EP3394055B1 (en) | Pyrrolo[3,2-c]pyridine-6-amino derivatives | |
Yan et al. | Discovery of novel 2, 4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation | |
EP2986605B1 (en) | Rohitukine analogs as cyclin-dependent kinase inhibitors and a process for the preparation thereof | |
CN113840823A (zh) | 显示癌细胞生长抑制效果的新型杂环取代的嘧啶衍生物,以及包含其的药物组合物 | |
KR20180052631A (ko) | 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도 | |
WO2021126118A1 (en) | Synthesis of 2-(substitutedphenyl)-5-(substitutedheteroaryl)- 1h-benzimidazole derivatives and investigation of their biological effects | |
CN116655600A (zh) | 一种取代的2-芳氨基嘧啶类化合物、药物组合物及其用途 | |
CN115703760A (zh) | 2,4-二取代嘧啶类细胞周期蛋白依赖性激酶酶抑制剂及其制备方法和应用 | |
PL237263B1 (pl) | Pochodna chinazoliny i jej zastosowanie | |
CN101268072A (zh) | Dna-pk抑制剂 | |
JP2017531003A (ja) | スルホン基を含有するフッ化ベンゾフラニル−ピリミジン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: LE SUN PHARMACEUTICALS LTD. Free format text: FORMER OWNER: CANCER REC TECH LTD. Effective date: 20141115 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; TO: 213022 CHANGZHOU, JIANGSU PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20141115 Address after: The New District National High Tech Development Zone in Jiangsu Province, Changzhou City, 213022 West Road No. 106 Applicant after: Le Sun Pharmaceuticals Ltd. Address before: London, England Applicant before: Cancer Rec Tech Ltd. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20131030 Assignee: Changzhou Qianhong Biopharma Co., Ltd. Assignor: Le Sun Pharmaceuticals Ltd. Contract record no.: 2017990000383 Denomination of invention: Methods for testing of therapeutic compounds Granted publication date: 20170503 License type: Exclusive License Record date: 20170921 |